Alphabet Inc.'s Form 4 filing
Oscar Health, Inc. (OSCR) · filed Aug 21, 2023
- Accession no.
- 0000929638-23-002316
- Filed
- Aug 21, 2023, 4:30 PM ET
- Trade date
- Aug 17, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $52.5M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Alphabet Inc.CIK 0001652044 | 10% Owner |
| CapitalG LPCIK 0001678225 | 10% Owner |
| CapitalG GP LLCCIK 0001678226 | 10% Owner |
| GV 2014 GP, L.L.C.CIK 0001728736 | 10% Owner |
| GV 2014, L.P.CIK 0001728797 | 10% Owner |
| CapitalG 2015 LPCIK 0001771167 | 10% Owner |
| CapitalG 2015 GP LLCCIK 0001779431 | 10% Owner |
| Alphabet Holdings LLCCIK 0001847337 | 10% Owner |
| Verily Life Sciences LLCCIK 0001848282 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2023 | Class A Common Stock | SSaleDisposed | −5,719,438 | $8.08F1 | −$46,218,778.48 | 15,625,310 | Indirect | |
| Aug 17, 2023 | Class A Common Stock | SSaleDisposed | −525,470 | $8.08F1 | −$4,246,323.07 | 1,180,474 | Indirect | |
| Aug 17, 2023 | Class A Common Stock | SSaleDisposed | −255,092 | $8.08F1 | −$2,061,398.45 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On August 17, 2023, (i) Alphabet Holdings LLC sold 5,719,438 shares of Class A Common Stock ("Common Shares"), (ii) CapitalG 2015 LP sold 525,470 Common Shares, and (iii) Verily Life Sciences LLC sold 255,092 Common Shares to an unaffiliated financial institution pursuant to a post-paid forward transaction at a price based on the volume weighted average price of the Common Shares over a period of time determined by the financial institution, subject to an agreed minimum and maximum period.
Referenced by the price of 3 transactions in Table I.